ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Not Junk but Magic

<< Previous

Bullboard Posts

Next >>

Comment by Annayyaon Aug 24, 2021 12:11pm

93 Views

Post# 33754984

RE:RE:Not Junk but Magic

I am surprised with how well the share price is holding, despite the massive dilution at 16 cents and warrants. I was hoping to buy more shares at 16 cents, but I have doesn't look like that will happen.

M101 wrote: Sounds like a good plan B, given that plan A (producing a saleable product) doesn't seem to be happening, cause you know "not first in class"

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1